文献速递药物相互作用药物不良反应与药物警戒

阿瑞匹坦与福沙匹坦的药物相互作用系统综述

Aprepitant and fosaprepitant drug interactions: a systematic review.
PubMed 文献 · Br J Clin Pharmacol · 2017-06-10

该系统综述检索至2016年9月11日的文献,评估阿瑞匹坦/福沙匹坦相关的药代动力学相互作用及不良事件。共纳入64篇文献,识别出与博舒替尼、卡巴他赛、环磷酰胺、地塞米松、甲泼尼龙、咪达唑仑、羟考酮、甲苯磺丁脲等的临床显著相互作用,以及酒精、蒽环类、异环磷酰胺、喹硫平、SSRI/SNRI、华法林相关不良事件。

要点

  • 阿瑞匹坦/福沙匹坦与多种药物存在临床显著药代动力学相互作用。
  • 选择止吐方案时应考虑阿瑞匹坦/福沙匹坦的药物相互作用潜力。
  • 不良事件涉及酒精、蒽环类、异环磷酰胺、羟考酮、喹硫平、SSRI/SNRI和华法林。

核心结论

  • 选择止吐治疗时应考虑阿瑞匹坦和福沙匹坦潜在的药物相互作用。

研究设计与样本

  • 系统综述检索文献至2016年9月11日,共识别4377篇出版物,64篇符合纳入标准。
  • 34篇描述药代动力学药物相互作用,30篇描述归因于药物相互作用的不良事件。
  • 药代动力学相互作用临床意义依据美国FDA药物相互作用研究指南评估。
  • 不良事件与药物相互作用的概率采用药物相互作用概率量表判定。

主要发现

  • 阿瑞匹坦/福沙匹坦与博舒替尼口服、卡巴他赛静脉、环磷酰胺静脉、地塞米松口服、甲泼尼龙静脉、咪达唑仑口服/静脉、羟考酮口服和甲苯磺丁脲口服存在临床显著药代动力学相互作用。
  • 阿瑞匹坦/福沙匹坦与酒精、蒽环类、异环磷酰胺、羟考酮、喹硫平、选择性5-羟色胺再摄取抑制剂/5-羟色胺-去甲肾上腺素再摄取抑制剂及华法林相互作用可导致不良事件。

临床怎么用

  • 在选用阿瑞匹坦或福沙匹坦作为止吐治疗时,应评估患者合并用药并考虑相互作用的潜在风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy-induced nausea and vomiting, alter cytochrome P450 activity. This systematic review evaluates clinically significant pharmacokinetic drug interactions with aprepitant and fosaprepitant and describes adverse events ascribed to drug interactions with aprepitant or fosaprepitant. METHODS: We systematically reviewed the literature to September 11, 2016, to identify articles evaluating drug interactions involving aprepitant/fosaprepitant. The clinical significance of each reported pharmacokinetic drug interaction was evaluated based on the United States Food and Drug Administration guidance document on conducting drug interaction studies. The probability of an adverse event reported in case reports being due to a drug interaction with aprepitant/fosaprepitant was determined using the Drug Interaction Probability Scale. RESULTS: A total of 4377 publications were identified. Of these, 64 met inclusion eligibility criteria: 34 described pharmacokinetic drug interactions and 30 described adverse events ascribed to a drug interaction. Clinically significant pharmacokinetic interactions between aprepitant/fosaprepitant and bosutinib PO, cabazitaxel IV, cyclophosphamide IV, dexamethasone PO, methylprednisolone IV, midazolam PO/IV, oxycodone PO and tolbutamide PO were identified, as were adverse events resulting from an interaction between aprepitant/fosaprepitant and alcohol, anthracyclines, ifosfamide, oxycodone, quetiapine, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors and warfarin. CONCLUSIONS: The potential for a drug interaction with aprepitant and fosaprepitant should be considered when selecting antiemetic therapy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Patel P, Leeder JS, Piquette-Miller M, et al. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017. PMID: 28470980. doi:10.1111/bcp.13322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。